General Information of Drug (ID: DM05WXD)

Drug Name
2,3-diamino-benzo[b]thiophene derivative 5 Drug Info
Synonyms PMID27172114-Compound-36
Cross-matching ID
TTD Drug ID
DM05WXD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DN1406131 DMQFX8R Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
HTI-1090 DMI4TEC Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
2,3-diamino-benzo[b]thiophene derivative 4 DMEDFNC N. A. N. A. Patented [1]
PMID27172114-Compound-30 DMBWLSA N. A. N. A. Patented [1]
2,3-diamino-benzo[b]thiophene derivative 2 DMDYXKT N. A. N. A. Patented [1]
2,3-diamino-benzo[b]thiophene derivative 8 DM5O8K0 N. A. N. A. Patented [1]
2,3-diamino-benzo[b]thiophene derivative 7 DMQVMNJ N. A. N. A. Patented [1]
2,3-diamino-benzo[b]thiophene derivative 6 DMINE6V N. A. N. A. Patented [1]
2,3-diamino-benzo[b]thiophene derivative 1 DMD2KRW N. A. N. A. Patented [1]
2,3-diamino-benzo[b]thiophene derivative 3 DMR7QKL N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2,3-diamino-benzo[b]thiophene derivative 4 DMEDFNC N. A. N. A. Patented [1]
PMID27172114-Compound-30 DMBWLSA N. A. N. A. Patented [1]
2,3-diamino-benzo[b]thiophene derivative 2 DMDYXKT N. A. N. A. Patented [1]
2,3-diamino-benzo[b]thiophene derivative 8 DM5O8K0 N. A. N. A. Patented [1]
2,3-diamino-benzo[b]thiophene derivative 7 DMQVMNJ N. A. N. A. Patented [1]
2,3-diamino-benzo[b]thiophene derivative 6 DMINE6V N. A. N. A. Patented [1]
2,3-diamino-benzo[b]thiophene derivative 1 DMD2KRW N. A. N. A. Patented [1]
⏷ Show the Full List of 7 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Tryptophan DMIBH7M Depression 6A70-6A7Z Approved [4]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [5]
BMS-986205 DM3MAYQ Melanoma 2C30 Phase 3 [6]
INCB24360 DMIJGT9 Urothelial carcinoma 2C92.0 Phase 3 [7]
NLG8189 DM0798Z Melanoma 2C30 Phase 2/3 [6]
DN1406131 DMQFX8R Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
HTI-1090 DMI4TEC Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
KHK2455 DMLSUQ8 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
LY3381916 DMONZ1L Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
PF-06840003 DMOX6EJ Glioma 2A00.0 Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Indoleamine 2,3-dioxygenase 1 (IDO1) TTZJYKH I23O1_HUMAN Inhibitor [1]
Indoleamine 2,3-dioxygenase 2 (IDO2) TTALN9W I23O2_HUMAN Inhibitor [1]
Tryptophan 2,3-dioxygenase (TDO) TTXNCBV T23O_HUMAN Inhibitor [1]

References

1 Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.
2 ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
3 Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
4 Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
5 Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Incyte. Product Development Pipeline.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)